Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Exploring Next-Generation High DAR Dual Payload ADCs Featuring Novel Payloads to Enhance Efficacy, Overcome Resistance & Improve Safety

By | 8 June 2026

Leveraging a cutting-edge cell free platform and novel payload classes to discover high-DAR dual payload ADCs aimed at overcoming resistance to single payload ADCs
Demonstrating synergistic efficacy of Topo1-based combinations with diverse mechanisms, including DDR inhibitors, to enhance anti-tumor activity
Validating improved preclinical efficacy of dual payload ADCs across in vitro and in vivo/PDX models to support their potential in resistant tumor settings